Prediction of survival after eribulin chemotherapy for breast cancer by absolute lymphocyte counts and progression types
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1477-7819
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Prediction of survival after eribulin chemotherapy for breast cancer by absolute lymphocyte counts and progression types ; volume:19 ; number:1 ; day:15 ; month:11 ; year:2021 ; pages:1-9 ; date:12.2021
World journal of surgical oncology ; 19, Heft 1 (15.11.2021), 1-9, 12.2021
- Creator
-
Morisaki, Tamami
Kashiwagi, Shinichiro
Asano, Yuka
Goto, Wataru
Takada, Koji
Ishihara, Sae
Shibutani, Masatsune
Tanaka, Hiroaki
Hirakawa, Kosei
Ohira, Masaichi
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12957-021-02441-w
- URN
-
urn:nbn:de:101:1-2022012519052348212731
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:26 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Morisaki, Tamami
- Kashiwagi, Shinichiro
- Asano, Yuka
- Goto, Wataru
- Takada, Koji
- Ishihara, Sae
- Shibutani, Masatsune
- Tanaka, Hiroaki
- Hirakawa, Kosei
- Ohira, Masaichi
- SpringerLink (Online service)
Other Objects (12)
Monitoring trends in the absolute lymphocyte count and the neutrophil-to-lymphocyte ratio in patients with breast cancer receiving eribulin
Absolute lymphocyte count as a marker for CD4 lymphocyte count: criterion for initiating antiretroviral therapy in HIV-infected Nigerians
Absolute lymphocyte count predicts efficacy of palbociclib in patients with metastatic luminal breast cancer
Absolute lymphocyte count and neutrophil-to-lymphocyte ratio as predictors of CDK 4/6 inhibitor efficacy in advanced breast cancer
Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel
Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes
High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin—but not with treatment of physician’s choice—in the EMBRACE study
Utility of total lymphocyte count as a surrogate for absolute CD4 count in the adult Indian HIV population: A prospective study
The predictive value of absolute lymphocyte counts on tumor progression and pseudoprogression in patients with glioblastoma
Preoperative low absolute lymphocyte count to fibrinogen ratio correlated with poor survival in nonmetastatic colorectal cancer
Eribulin drug review
Low lymphocyte count and high monocyte count predicts poor prognosis of gastric cancer
Monitoring trends in the absolute lymphocyte count and the neutrophil-to-lymphocyte ratio in patients with breast cancer receiving eribulin
Absolute lymphocyte count as a marker for CD4 lymphocyte count: criterion for initiating antiretroviral therapy in HIV-infected Nigerians
Absolute lymphocyte count predicts efficacy of palbociclib in patients with metastatic luminal breast cancer
Absolute lymphocyte count and neutrophil-to-lymphocyte ratio as predictors of CDK 4/6 inhibitor efficacy in advanced breast cancer
Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel
Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes
High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin—but not with treatment of physician’s choice—in the EMBRACE study
Utility of total lymphocyte count as a surrogate for absolute CD4 count in the adult Indian HIV population: A prospective study
The predictive value of absolute lymphocyte counts on tumor progression and pseudoprogression in patients with glioblastoma
Preoperative low absolute lymphocyte count to fibrinogen ratio correlated with poor survival in nonmetastatic colorectal cancer
Eribulin drug review
Low lymphocyte count and high monocyte count predicts poor prognosis of gastric cancer
Monitoring trends in the absolute lymphocyte count and the neutrophil-to-lymphocyte ratio in patients with breast cancer receiving eribulin
Absolute lymphocyte count as a marker for CD4 lymphocyte count: criterion for initiating antiretroviral therapy in HIV-infected Nigerians
Absolute lymphocyte count predicts efficacy of palbociclib in patients with metastatic luminal breast cancer
Absolute lymphocyte count and neutrophil-to-lymphocyte ratio as predictors of CDK 4/6 inhibitor efficacy in advanced breast cancer
Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel
Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes
High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin—but not with treatment of physician’s choice—in the EMBRACE study
Utility of total lymphocyte count as a surrogate for absolute CD4 count in the adult Indian HIV population: A prospective study
The predictive value of absolute lymphocyte counts on tumor progression and pseudoprogression in patients with glioblastoma
Preoperative low absolute lymphocyte count to fibrinogen ratio correlated with poor survival in nonmetastatic colorectal cancer
Eribulin drug review